Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Argenx nets $531.8mm through concurrent global public ADS offering/European private placement

Executive Summary

Euronext Brussels- and Nasdaq-traded argenx SE (antibody-based therapies for severe autoimmune diseases and cancer) completed the simultaneous global sale (in countries outside Europe) of American Depositary Shares (ADSs) and a European private placement; together constituting a single offering. In the global public sale, argenx sold 2mm ADSs (including the overallotment) at $121, netting $232.4mm. (Each ADS is equivalent to one ordinary share.) The European private placement netted $299.4mm and consisted of 2.6mm ordinary shares at €109.18 ($121) apiece.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • FOPO

Related Companies